• Explore /
  • Poster
  • / A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).

Abstract Video & Slides Poster

Authors

Amita Patnaik

Amita Patnaik

START, San Antonio, TX

Amita Patnaik , Emiliano Calvo , Sarina Anne Anne Piha-Paul , Antoine Hollebecque , Vladimir Galvao , Juanita Suzanne Lopez , Fadi S. Braiteh , Rachel E. Sanborn , Peigen Zhou , Natalya N. Nazarenko , Afshin Dowlati

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04389632

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS3144)

DOI

10.1200/JCO.2021.39.15_suppl.TPS3144

Abstract #

TPS3144

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Antoine Hollebecque

First Author: Ning Li

First Author: Susanna Varkey Ulahannan

First Author: Yoon-Koo Kang